| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Atrophy, Spinal | 7 | 2022 | 20 | 3.610 |
Why?
|
| Maple Syrup Urine Disease | 11 | 2025 | 18 | 3.250 |
Why?
|
| Liver Transplantation | 14 | 2021 | 217 | 2.900 |
Why?
|
| Child, Preschool | 47 | 2024 | 2018 | 2.570 |
Why?
|
| Infant | 43 | 2024 | 1664 | 2.480 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 3 | 2024 | 5 | 2.340 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 8 | 2020 | 11 | 2.040 |
Why?
|
| Homozygote | 15 | 2020 | 124 | 1.920 |
Why?
|
| Brain | 15 | 2021 | 1581 | 1.900 |
Why?
|
| Child | 47 | 2023 | 4583 | 1.880 |
Why?
|
| Amish | 10 | 2022 | 10 | 1.750 |
Why?
|
| Epilepsy | 9 | 2023 | 110 | 1.680 |
Why?
|
| Infant, Newborn | 24 | 2024 | 1375 | 1.610 |
Why?
|
| Troponin T | 3 | 2025 | 24 | 1.610 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2025 | 727 | 1.520 |
Why?
|
| Sialyltransferases | 6 | 2023 | 18 | 1.500 |
Why?
|
| Glutaryl-CoA Dehydrogenase | 6 | 2020 | 6 | 1.440 |
Why?
|
| Survival of Motor Neuron 1 Protein | 2 | 2024 | 7 | 1.440 |
Why?
|
| Survival of Motor Neuron 2 Protein | 4 | 2024 | 6 | 1.380 |
Why?
|
| Crigler-Najjar Syndrome | 5 | 2022 | 5 | 1.360 |
Why?
|
| Oligonucleotides | 3 | 2024 | 226 | 1.320 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2015 | 497 | 1.200 |
Why?
|
| Adolescent | 35 | 2023 | 6304 | 1.190 |
Why?
|
| Phenotype | 20 | 2021 | 1222 | 1.120 |
Why?
|
| Muscle, Skeletal | 3 | 2025 | 747 | 1.110 |
Why?
|
| Mutation | 23 | 2023 | 2629 | 1.100 |
Why?
|
| Humans | 99 | 2025 | 64238 | 1.080 |
Why?
|
| Female | 65 | 2025 | 33350 | 1.040 |
Why?
|
| Male | 59 | 2025 | 30294 | 1.040 |
Why?
|
| Brain Diseases, Metabolic | 2 | 2020 | 3 | 1.020 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2019 | 38 | 1.000 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 4 | 2025 | 9 | 0.990 |
Why?
|
| Osteochondrodysplasias | 4 | 2017 | 11 | 0.960 |
Why?
|
| Pedigree | 17 | 2025 | 195 | 0.960 |
Why?
|
| Amino Acids, Branched-Chain | 5 | 2021 | 13 | 0.950 |
Why?
|
| Heart Defects, Congenital | 3 | 2017 | 104 | 0.930 |
Why?
|
| Corpus Striatum | 3 | 2020 | 97 | 0.930 |
Why?
|
| Muscular Diseases | 2 | 2023 | 51 | 0.900 |
Why?
|
| Habenula | 1 | 2025 | 15 | 0.900 |
Why?
|
| Ellis-Van Creveld Syndrome | 2 | 2017 | 7 | 0.890 |
Why?
|
| Genetic Therapy | 4 | 2025 | 802 | 0.860 |
Why?
|
| Gangliosides | 3 | 2023 | 19 | 0.850 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 129 | 0.840 |
Why?
|
| Mutation, Missense | 6 | 2025 | 185 | 0.840 |
Why?
|
| Brain Diseases | 2 | 2020 | 78 | 0.830 |
Why?
|
| Leucine | 4 | 2020 | 67 | 0.820 |
Why?
|
| Myopathies, Nemaline | 2 | 2025 | 2 | 0.820 |
Why?
|
| Chromosome Mapping | 8 | 2012 | 290 | 0.810 |
Why?
|
| Heterozygote | 5 | 2022 | 171 | 0.780 |
Why?
|
| Microcephaly | 4 | 2019 | 14 | 0.770 |
Why?
|
| Injections, Spinal | 2 | 2021 | 46 | 0.760 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 4 | 2009 | 6 | 0.750 |
Why?
|
| Arginine | 2 | 2014 | 131 | 0.730 |
Why?
|
| Muscle Weakness | 2 | 2020 | 33 | 0.730 |
Why?
|
| Young Adult | 23 | 2022 | 4776 | 0.730 |
Why?
|
| Bilirubin | 3 | 2022 | 18 | 0.730 |
Why?
|
| Phototherapy | 3 | 2020 | 36 | 0.720 |
Why?
|
| Developmental Disabilities | 6 | 2017 | 116 | 0.700 |
Why?
|
| Genetic Testing | 4 | 2017 | 140 | 0.690 |
Why?
|
| Carbon-Carbon Ligases | 1 | 2020 | 1 | 0.670 |
Why?
|
| Propionic Acidemia | 1 | 2020 | 1 | 0.670 |
Why?
|
| Stress, Psychological | 1 | 2025 | 479 | 0.660 |
Why?
|
| Adult | 29 | 2020 | 17116 | 0.640 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2020 | 41 | 0.640 |
Why?
|
| Membrane Proteins | 5 | 2021 | 909 | 0.640 |
Why?
|
| Serum Albumin | 1 | 2020 | 46 | 0.630 |
Why?
|
| Living Donors | 2 | 2019 | 78 | 0.620 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2008 | 8 | 0.620 |
Why?
|
| Depression | 2 | 2025 | 909 | 0.610 |
Why?
|
| Genetics, Medical | 2 | 2017 | 11 | 0.610 |
Why?
|
| Tyrosine-tRNA Ligase | 1 | 2019 | 2 | 0.600 |
Why?
|
| Gene Dosage | 2 | 2018 | 65 | 0.600 |
Why?
|
| Heart | 2 | 2020 | 288 | 0.600 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 23 | 0.590 |
Why?
|
| Glycine N-Methyltransferase | 2 | 2016 | 2 | 0.590 |
Why?
|
| Liver Cirrhosis | 2 | 2020 | 180 | 0.580 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2018 | 8 | 0.580 |
Why?
|
| Craniofacial Abnormalities | 2 | 2017 | 22 | 0.580 |
Why?
|
| Biomarkers | 3 | 2021 | 1431 | 0.560 |
Why?
|
| N-Acetylgalactosaminyltransferases | 2 | 2017 | 3 | 0.560 |
Why?
|
| Catheterization | 1 | 2018 | 113 | 0.560 |
Why?
|
| Sequence Analysis, DNA | 5 | 2016 | 416 | 0.560 |
Why?
|
| Codon, Nonsense | 2 | 2018 | 58 | 0.540 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2020 | 62 | 0.530 |
Why?
|
| Genetic Association Studies | 5 | 2017 | 120 | 0.510 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 89 | 0.500 |
Why?
|
| Deafness | 1 | 2017 | 41 | 0.500 |
Why?
|
| Exome | 3 | 2015 | 77 | 0.490 |
Why?
|
| Nerve Tissue Proteins | 5 | 2021 | 429 | 0.490 |
Why?
|
| Bipolar Disorder | 2 | 2019 | 247 | 0.490 |
Why?
|
| DNA, Mitochondrial | 2 | 2015 | 87 | 0.480 |
Why?
|
| Cell Cycle | 2 | 2015 | 396 | 0.470 |
Why?
|
| Genomics | 2 | 2017 | 379 | 0.470 |
Why?
|
| Eye Abnormalities | 2 | 2015 | 21 | 0.470 |
Why?
|
| Progesterone Reductase | 1 | 2015 | 1 | 0.470 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2015 | 5 | 0.460 |
Why?
|
| Nephrosis | 1 | 2015 | 4 | 0.460 |
Why?
|
| Tooth Abnormalities | 1 | 2015 | 2 | 0.450 |
Why?
|
| Hip Dislocation, Congenital | 1 | 2015 | 3 | 0.450 |
Why?
|
| Hernia, Hiatal | 1 | 2015 | 27 | 0.450 |
Why?
|
| Haplotypes | 2 | 2013 | 134 | 0.450 |
Why?
|
| ATP-Dependent Proteases | 1 | 2015 | 7 | 0.450 |
Why?
|
| Serine Proteases | 1 | 2015 | 12 | 0.450 |
Why?
|
| Growth Disorders | 1 | 2015 | 29 | 0.440 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2014 | 7 | 0.430 |
Why?
|
| Mice | 18 | 2025 | 11003 | 0.430 |
Why?
|
| Histidine | 1 | 2014 | 34 | 0.420 |
Why?
|
| Carnitine | 3 | 2020 | 20 | 0.420 |
Why?
|
| Hearing Loss, Central | 1 | 2013 | 2 | 0.420 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 106 | 0.420 |
Why?
|
| Neonatal Screening | 5 | 2022 | 102 | 0.420 |
Why?
|
| Pennsylvania | 10 | 2021 | 64 | 0.410 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 2 | 2003 | 8 | 0.410 |
Why?
|
| Putamen | 2 | 2003 | 21 | 0.410 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 2478 | 0.400 |
Why?
|
| Abnormalities, Multiple | 2 | 2012 | 54 | 0.400 |
Why?
|
| Adenine Nucleotide Translocator 1 | 1 | 2013 | 1 | 0.400 |
Why?
|
| Aspartic Acid | 1 | 2013 | 34 | 0.390 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 374 | 0.390 |
Why?
|
| Glutamic Acid | 1 | 2013 | 101 | 0.380 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2012 | 44 | 0.370 |
Why?
|
| Seizures | 4 | 2019 | 143 | 0.370 |
Why?
|
| Glycosphingolipids | 2 | 2023 | 9 | 0.360 |
Why?
|
| Cystathionine beta-Synthase | 2 | 2008 | 5 | 0.360 |
Why?
|
| Animals | 21 | 2025 | 20961 | 0.350 |
Why?
|
| Glutarates | 3 | 2008 | 10 | 0.350 |
Why?
|
| Homocysteine | 2 | 2008 | 33 | 0.350 |
Why?
|
| Genotype | 7 | 2019 | 668 | 0.350 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 130 | 0.340 |
Why?
|
| Retrospective Studies | 11 | 2021 | 6726 | 0.340 |
Why?
|
| Diet | 3 | 2020 | 533 | 0.340 |
Why?
|
| Proteins | 3 | 2015 | 760 | 0.330 |
Why?
|
| Treatment Outcome | 7 | 2024 | 5691 | 0.320 |
Why?
|
| Biological Products | 2 | 2022 | 99 | 0.320 |
Why?
|
| Food, Formulated | 1 | 2010 | 10 | 0.320 |
Why?
|
| Intellectual Disability | 3 | 2021 | 172 | 0.320 |
Why?
|
| Lysine | 3 | 2020 | 87 | 0.300 |
Why?
|
| Genetics, Population | 1 | 2009 | 44 | 0.290 |
Why?
|
| Endoribonucleases | 1 | 2009 | 56 | 0.290 |
Why?
|
| Alleles | 3 | 2019 | 448 | 0.290 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 183 | 0.290 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 2238 | 0.280 |
Why?
|
| Histocompatibility Testing | 1 | 2008 | 32 | 0.280 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2008 | 34 | 0.280 |
Why?
|
| HLA Antigens | 1 | 2008 | 63 | 0.280 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2008 | 54 | 0.270 |
Why?
|
| Ribonucleoproteins | 1 | 2009 | 116 | 0.270 |
Why?
|
| Betaine | 1 | 2007 | 10 | 0.260 |
Why?
|
| Homeostasis | 2 | 2025 | 369 | 0.260 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 297 | 0.260 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2010 | 270 | 0.250 |
Why?
|
| Mitochondria | 3 | 2020 | 384 | 0.250 |
Why?
|
| Glucuronosyltransferase | 3 | 2022 | 11 | 0.250 |
Why?
|
| Stereocilia | 2 | 2017 | 6 | 0.250 |
Why?
|
| Hair Cells, Auditory | 2 | 2017 | 15 | 0.250 |
Why?
|
| Epilepsies, Partial | 1 | 2006 | 18 | 0.240 |
Why?
|
| Kernicterus | 1 | 2006 | 1 | 0.240 |
Why?
|
| Methionine | 3 | 2015 | 57 | 0.240 |
Why?
|
| Middle Aged | 15 | 2020 | 17898 | 0.240 |
Why?
|
| Mice, Knockout | 7 | 2025 | 2140 | 0.240 |
Why?
|
| Sialic Acid Storage Disease | 1 | 2005 | 1 | 0.240 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2019 | 49 | 0.240 |
Why?
|
| Cohort Studies | 4 | 2020 | 2604 | 0.230 |
Why?
|
| Amino Acids | 2 | 2020 | 148 | 0.230 |
Why?
|
| CRADD Signaling Adaptor Protein | 2 | 2016 | 2 | 0.220 |
Why?
|
| Metabolic Diseases | 3 | 2020 | 58 | 0.220 |
Why?
|
| Hirschsprung Disease | 2 | 2017 | 7 | 0.220 |
Why?
|
| Azo Compounds | 1 | 2024 | 6 | 0.220 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2017 | 73 | 0.210 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2025 | 107 | 0.200 |
Why?
|
| Postoperative Complications | 3 | 2021 | 1294 | 0.200 |
Why?
|
| Homeodomain Proteins | 1 | 2025 | 272 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2024 | 146 | 0.200 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 374 | 0.200 |
Why?
|
| Echocardiography | 2 | 2020 | 509 | 0.200 |
Why?
|
| Neurons | 4 | 2021 | 934 | 0.200 |
Why?
|
| Case-Control Studies | 4 | 2015 | 1130 | 0.190 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2014 | 34 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2023 | 3315 | 0.190 |
Why?
|
| Time Factors | 4 | 2017 | 3724 | 0.190 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2022 | 8 | 0.190 |
Why?
|
| Prognosis | 3 | 2019 | 1769 | 0.180 |
Why?
|
| Apc7 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2021 | 1 | 0.180 |
Why?
|
| Abortion, Spontaneous | 1 | 2022 | 31 | 0.180 |
Why?
|
| Cost of Illness | 2 | 2022 | 169 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1561 | 0.180 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2017 | 644 | 0.180 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2021 | 8 | 0.180 |
Why?
|
| S-Adenosylmethionine | 2 | 2015 | 28 | 0.180 |
Why?
|
| Signal Transduction | 6 | 2023 | 3070 | 0.180 |
Why?
|
| Neural Stem Cells | 1 | 2021 | 48 | 0.180 |
Why?
|
| Prosencephalon | 1 | 2021 | 37 | 0.180 |
Why?
|
| Corpus Callosum | 2 | 2015 | 42 | 0.170 |
Why?
|
| Catheters | 1 | 2021 | 78 | 0.170 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 1 | 2021 | 11 | 0.170 |
Why?
|
| Neurogenesis | 1 | 2021 | 64 | 0.170 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 11 | 0.170 |
Why?
|
| Organoids | 1 | 2021 | 45 | 0.170 |
Why?
|
| Heterochromatin | 1 | 2021 | 89 | 0.170 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2020 | 2 | 0.170 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2020 | 6 | 0.170 |
Why?
|
| Acids | 1 | 2020 | 14 | 0.170 |
Why?
|
| Central Nervous System Diseases | 2 | 2013 | 58 | 0.170 |
Why?
|
| Organic Chemicals | 1 | 2020 | 24 | 0.170 |
Why?
|
| G(M3) Ganglioside | 2 | 2023 | 3 | 0.170 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 296 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 495 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2022 | 156 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 1494 | 0.160 |
Why?
|
| Liver | 4 | 2025 | 868 | 0.160 |
Why?
|
| Risk Assessment | 2 | 2020 | 2046 | 0.160 |
Why?
|
| Necrosis | 3 | 2007 | 144 | 0.160 |
Why?
|
| Axons | 1 | 2020 | 126 | 0.160 |
Why?
|
| Workflow | 2 | 2017 | 71 | 0.160 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2012 | 224 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2019 | 37 | 0.150 |
Why?
|
| Models, Biological | 2 | 2010 | 1187 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2019 | 34 | 0.150 |
Why?
|
| Isoleucine | 3 | 2016 | 8 | 0.150 |
Why?
|
| Apgar Score | 1 | 2019 | 11 | 0.150 |
Why?
|
| Yeasts | 1 | 2019 | 49 | 0.150 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 704 | 0.150 |
Why?
|
| Disease Progression | 2 | 2013 | 1176 | 0.150 |
Why?
|
| Genetic Vectors | 2 | 2025 | 889 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 423 | 0.150 |
Why?
|
| Apoptosis | 2 | 2016 | 1094 | 0.150 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 11 | 0.140 |
Why?
|
| Proteolysis | 2 | 2021 | 149 | 0.140 |
Why?
|
| Dependovirus | 2 | 2025 | 721 | 0.140 |
Why?
|
| Hair | 2 | 2017 | 83 | 0.140 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 180 | 0.140 |
Why?
|
| Catalytic Domain | 1 | 2019 | 205 | 0.140 |
Why?
|
| Graft Rejection | 1 | 2019 | 302 | 0.140 |
Why?
|
| Protein Isoforms | 1 | 2018 | 199 | 0.140 |
Why?
|
| Respiratory Rate | 1 | 2017 | 15 | 0.140 |
Why?
|
| Dwarfism | 1 | 2017 | 15 | 0.140 |
Why?
|
| Haploinsufficiency | 1 | 2017 | 17 | 0.140 |
Why?
|
| Thoracotomy | 1 | 2017 | 47 | 0.130 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2017 | 48 | 0.130 |
Why?
|
| Hospitalization | 3 | 2011 | 1368 | 0.130 |
Why?
|
| Base Sequence | 4 | 2015 | 1332 | 0.130 |
Why?
|
| Outpatients | 1 | 2018 | 140 | 0.130 |
Why?
|
| Valine | 2 | 2016 | 33 | 0.130 |
Why?
|
| Incidental Findings | 1 | 2017 | 46 | 0.130 |
Why?
|
| Hearing | 1 | 2017 | 33 | 0.130 |
Why?
|
| Telomere Homeostasis | 1 | 2017 | 4 | 0.130 |
Why?
|
| United States | 3 | 2020 | 7923 | 0.130 |
Why?
|
| Creatine | 2 | 2016 | 24 | 0.130 |
Why?
|
| Membrane Microdomains | 1 | 2017 | 50 | 0.130 |
Why?
|
| Organogenesis | 1 | 2017 | 39 | 0.130 |
Why?
|
| Lissencephaly | 1 | 2016 | 1 | 0.130 |
Why?
|
| Caspase 2 | 1 | 2016 | 7 | 0.130 |
Why?
|
| Megalencephaly | 1 | 2016 | 5 | 0.130 |
Why?
|
| DNA | 3 | 2011 | 844 | 0.130 |
Why?
|
| Spinal Fusion | 1 | 2018 | 152 | 0.130 |
Why?
|
| Telomere | 1 | 2017 | 53 | 0.130 |
Why?
|
| RNA, Long Noncoding | 2 | 2017 | 170 | 0.130 |
Why?
|
| Weight Gain | 1 | 2017 | 168 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 2 | 2025 | 140 | 0.120 |
Why?
|
| Pain Management | 1 | 2018 | 169 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2616 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2016 | 627 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2017 | 209 | 0.120 |
Why?
|
| Cysteine Endopeptidases | 1 | 2016 | 97 | 0.120 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2016 | 18 | 0.120 |
Why?
|
| Alu Elements | 1 | 2016 | 9 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2014 | 518 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 203 | 0.120 |
Why?
|
| Genomic Imprinting | 1 | 2016 | 49 | 0.120 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2015 | 26 | 0.120 |
Why?
|
| Brazil | 1 | 2016 | 100 | 0.120 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2015 | 2 | 0.120 |
Why?
|
| Diet, Protein-Restricted | 1 | 2015 | 12 | 0.120 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2015 | 3 | 0.120 |
Why?
|
| Hand Disinfection | 2 | 2006 | 18 | 0.120 |
Why?
|
| Diet Therapy | 1 | 2015 | 15 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 344 | 0.120 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2015 | 10 | 0.120 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2015 | 17 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 74 | 0.110 |
Why?
|
| Survival Rate | 3 | 2019 | 859 | 0.110 |
Why?
|
| Tissue Donors | 1 | 2016 | 154 | 0.110 |
Why?
|
| Tubulin | 1 | 2015 | 73 | 0.110 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 327 | 0.110 |
Why?
|
| Head | 1 | 2015 | 54 | 0.110 |
Why?
|
| Gene Frequency | 1 | 2015 | 123 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 82 | 0.110 |
Why?
|
| Genome, Human | 2 | 2009 | 240 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 71 | 0.110 |
Why?
|
| Algorithms | 2 | 2017 | 1028 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 128 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 136 | 0.110 |
Why?
|
| White Matter | 1 | 2015 | 123 | 0.110 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2013 | 9 | 0.100 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2013 | 8 | 0.100 |
Why?
|
| Movement Disorders | 1 | 2014 | 25 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2016 | 294 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 785 | 0.100 |
Why?
|
| Cell Line | 2 | 2021 | 2055 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 2015 | 202 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2015 | 540 | 0.100 |
Why?
|
| Kartagener Syndrome | 1 | 2013 | 7 | 0.100 |
Why?
|
| Aged | 7 | 2020 | 14648 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 674 | 0.100 |
Why?
|
| Psychomotor Agitation | 1 | 2013 | 19 | 0.100 |
Why?
|
| Syndrome | 4 | 2021 | 180 | 0.100 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 17 | 0.100 |
Why?
|
| Impulsive Behavior | 1 | 2013 | 28 | 0.100 |
Why?
|
| Sirolimus | 1 | 2013 | 94 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 313 | 0.090 |
Why?
|
| Gene Deletion | 2 | 2019 | 312 | 0.090 |
Why?
|
| Frameshift Mutation | 2 | 2010 | 29 | 0.090 |
Why?
|
| Mental Disorders | 1 | 2020 | 794 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 379 | 0.090 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2012 | 4 | 0.090 |
Why?
|
| Usher Syndromes | 1 | 2012 | 4 | 0.090 |
Why?
|
| Affect | 1 | 2013 | 127 | 0.090 |
Why?
|
| Parkinsonian Disorders | 1 | 2012 | 15 | 0.090 |
Why?
|
| Comorbidity | 1 | 2015 | 1118 | 0.090 |
Why?
|
| Receptors, Virus | 1 | 2012 | 73 | 0.090 |
Why?
|
| Stem Cells | 2 | 2010 | 262 | 0.090 |
Why?
|
| Attention | 1 | 2013 | 148 | 0.090 |
Why?
|
| Pyruvate Kinase | 1 | 2011 | 11 | 0.090 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2011 | 22 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2010 | 1540 | 0.090 |
Why?
|
| Growth and Development | 1 | 2011 | 9 | 0.090 |
Why?
|
| Protein Transport | 1 | 2012 | 405 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 113 | 0.090 |
Why?
|
| Isaacs Syndrome | 1 | 2011 | 1 | 0.090 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 44 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1257 | 0.090 |
Why?
|
| Dietary Proteins | 1 | 2011 | 44 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2012 | 136 | 0.090 |
Why?
|
| Myocardium | 1 | 2013 | 288 | 0.080 |
Why?
|
| Immunization | 1 | 2011 | 135 | 0.080 |
Why?
|
| Laminin | 1 | 2011 | 78 | 0.080 |
Why?
|
| Encephalitis | 1 | 2011 | 36 | 0.080 |
Why?
|
| Malformations of Cortical Development | 1 | 2010 | 5 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2011 | 150 | 0.080 |
Why?
|
| Thymus Gland | 1 | 2011 | 237 | 0.080 |
Why?
|
| Gene Expression | 2 | 2020 | 851 | 0.080 |
Why?
|
| Arterioles | 1 | 2009 | 7 | 0.080 |
Why?
|
| Nutritional Requirements | 1 | 2010 | 20 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 184 | 0.080 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2010 | 81 | 0.080 |
Why?
|
| Autoantigens | 1 | 2011 | 137 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 3450 | 0.080 |
Why?
|
| Vasoconstriction | 1 | 2009 | 22 | 0.080 |
Why?
|
| Blood Volume | 1 | 2009 | 40 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 343 | 0.080 |
Why?
|
| Anxiety | 1 | 2013 | 430 | 0.080 |
Why?
|
| Graft Survival | 2 | 2021 | 297 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 869 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 260 | 0.080 |
Why?
|
| Endocrine System Diseases | 1 | 2009 | 10 | 0.070 |
Why?
|
| Maryland | 1 | 2009 | 36 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2008 | 10 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 12 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2009 | 25 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 1407 | 0.070 |
Why?
|
| Protestantism | 2 | 2005 | 4 | 0.070 |
Why?
|
| Homocystinuria | 1 | 2008 | 5 | 0.070 |
Why?
|
| Open Reading Frames | 1 | 2008 | 85 | 0.070 |
Why?
|
| Fibrinogen | 1 | 2008 | 33 | 0.070 |
Why?
|
| Genes | 1 | 2008 | 90 | 0.070 |
Why?
|
| Genes, RAG-1 | 1 | 2008 | 8 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 443 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 233 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2010 | 348 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2007 | 2217 | 0.070 |
Why?
|
| Polyhydramnios | 1 | 2007 | 2 | 0.070 |
Why?
|
| Motor Skills Disorders | 1 | 2007 | 5 | 0.070 |
Why?
|
| Pregnancy | 4 | 2022 | 2370 | 0.070 |
Why?
|
| Hospital Communication Systems | 1 | 2006 | 3 | 0.060 |
Why?
|
| Tape Recording | 1 | 2006 | 13 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2009 | 215 | 0.060 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 3 | 2013 | 53 | 0.060 |
Why?
|
| Methyltransferases | 1 | 2007 | 63 | 0.060 |
Why?
|
| Personnel, Hospital | 1 | 2006 | 45 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 155 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2013 | 125 | 0.060 |
Why?
|
| Reflex, Stretch | 1 | 2006 | 2 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1019 | 0.060 |
Why?
|
| Inservice Training | 1 | 2006 | 87 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2009 | 1019 | 0.060 |
Why?
|
| Cholagogues and Choleretics | 1 | 2006 | 5 | 0.060 |
Why?
|
| Temporal Lobe | 1 | 2006 | 46 | 0.060 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2006 | 7 | 0.060 |
Why?
|
| Reminder Systems | 1 | 2006 | 75 | 0.060 |
Why?
|
| Sweetening Agents | 1 | 2006 | 21 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 220 | 0.060 |
Why?
|
| Multiprotein Complexes | 3 | 2013 | 155 | 0.060 |
Why?
|
| Siblings | 2 | 2020 | 43 | 0.060 |
Why?
|
| Organic Anion Transporters | 1 | 2005 | 6 | 0.060 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2005 | 6 | 0.060 |
Why?
|
| Albumins | 1 | 2006 | 37 | 0.060 |
Why?
|
| Symporters | 1 | 2005 | 18 | 0.060 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 49 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 176 | 0.060 |
Why?
|
| Basal Ganglia Diseases | 1 | 2005 | 5 | 0.060 |
Why?
|
| Guideline Adherence | 2 | 2006 | 306 | 0.060 |
Why?
|
| Gene Knock-In Techniques | 1 | 2025 | 43 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 672 | 0.060 |
Why?
|
| Electroencephalography | 1 | 2006 | 151 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2006 | 164 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1001 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2017 | 2176 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 186 | 0.060 |
Why?
|
| Th17 Cells | 1 | 2025 | 62 | 0.060 |
Why?
|
| Gonadal Dysgenesis | 1 | 2004 | 3 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2017 | 7 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2005 | 296 | 0.050 |
Why?
|
| Sudden Infant Death | 1 | 2004 | 24 | 0.050 |
Why?
|
| Cattle | 1 | 2025 | 316 | 0.050 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2023 | 19 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2016 | 128 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2007 | 756 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 17 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 552 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2003 | 22 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 1997 | 0.050 |
Why?
|
| Nitro Compounds | 1 | 2003 | 15 | 0.050 |
Why?
|
| Dystonia | 1 | 2003 | 13 | 0.050 |
Why?
|
| Computational Biology | 2 | 2017 | 357 | 0.050 |
Why?
|
| Propionates | 1 | 2003 | 24 | 0.050 |
Why?
|
| Malabsorption Syndromes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Tryptophan | 1 | 2003 | 56 | 0.050 |
Why?
|
| Acyltransferases | 1 | 2003 | 33 | 0.050 |
Why?
|
| Genes, Recessive | 2 | 2016 | 53 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1621 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2003 | 24 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 1597 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2025 | 219 | 0.050 |
Why?
|
| Glucose | 1 | 2006 | 470 | 0.050 |
Why?
|
| Cross Infection | 1 | 2004 | 167 | 0.050 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2022 | 13 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2022 | 19 | 0.050 |
Why?
|
| Pulse Wave Analysis | 1 | 2022 | 14 | 0.050 |
Why?
|
| Receptors, LDL | 1 | 2022 | 35 | 0.050 |
Why?
|
| Stillbirth | 1 | 2022 | 17 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 197 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2021 | 36 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 104 | 0.040 |
Why?
|
| Prednisolone | 1 | 2021 | 10 | 0.040 |
Why?
|
| Intelligence | 1 | 2021 | 52 | 0.040 |
Why?
|
| Cadherins | 1 | 2021 | 82 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2021 | 113 | 0.040 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 53 | 0.040 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2025 | 252 | 0.040 |
Why?
|
| COP-Coated Vesicles | 1 | 2020 | 2 | 0.040 |
Why?
|
| Pediatrics | 1 | 2003 | 261 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 5520 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 79 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2021 | 348 | 0.040 |
Why?
|
| Golgi Apparatus | 1 | 2020 | 64 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 180 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 218 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 182 | 0.040 |
Why?
|
| Hyperbilirubinemia | 1 | 2019 | 2 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 901 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 154 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2021 | 234 | 0.040 |
Why?
|
| Health Personnel | 1 | 2004 | 389 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2020 | 206 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2019 | 44 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 1669 | 0.040 |
Why?
|
| Motor Neurons | 1 | 2020 | 215 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2020 | 404 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 390 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2018 | 40 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 460 | 0.030 |
Why?
|
| Registries | 1 | 2022 | 885 | 0.030 |
Why?
|
| Parents | 1 | 2022 | 395 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1196 | 0.030 |
Why?
|
| Cleft Palate | 1 | 2017 | 40 | 0.030 |
Why?
|
| Dyskeratosis Congenita | 1 | 2017 | 3 | 0.030 |
Why?
|
| PC12 Cells | 1 | 2016 | 27 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 174 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2017 | 145 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1365 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 386 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5339 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2015 | 32 | 0.030 |
Why?
|
| Gray Matter | 1 | 2015 | 38 | 0.030 |
Why?
|
| Gyrus Cinguli | 1 | 2015 | 57 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2015 | 80 | 0.030 |
Why?
|
| Body Composition | 1 | 2015 | 153 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 86 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 1 | 2015 | 179 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 582 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 239 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 361 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2016 | 312 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 761 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 206 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 175 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2016 | 528 | 0.030 |
Why?
|
| Arkansas | 1 | 2013 | 4 | 0.020 |
Why?
|
| Family Health | 2 | 2004 | 69 | 0.020 |
Why?
|
| Cytarabine | 1 | 2013 | 38 | 0.020 |
Why?
|
| Wisconsin | 1 | 2013 | 17 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 84 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 2005 | 0.020 |
Why?
|
| Piperazines | 1 | 2013 | 87 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 491 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 387 | 0.020 |
Why?
|
| Zebrafish | 1 | 2015 | 350 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 614 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 677 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 2011 | 13 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1162 | 0.020 |
Why?
|
| Myasthenic Syndromes, Congenital | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pupil Disorders | 1 | 2011 | 4 | 0.020 |
Why?
|
| Nephrotic Syndrome | 1 | 2011 | 7 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2011 | 12 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 466 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 146 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 102 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 2011 | 33 | 0.020 |
Why?
|
| SOX Transcription Factors | 1 | 2010 | 1 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2010 | 12 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2010 | 18 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2011 | 103 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2010 | 48 | 0.020 |
Why?
|
| Consanguinity | 1 | 2010 | 6 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 131 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1681 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2010 | 89 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2010 | 85 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 110 | 0.020 |
Why?
|
| Disease Management | 1 | 2011 | 237 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 668 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 204 | 0.020 |
Why?
|
| Autopsy | 1 | 2009 | 56 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2009 | 173 | 0.020 |
Why?
|
| Species Specificity | 1 | 2009 | 334 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 201 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1272 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 129 | 0.020 |
Why?
|
| Psychomotor Disorders | 1 | 2007 | 7 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 1 | 2007 | 6 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 147 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 125 | 0.020 |
Why?
|
| Soaps | 1 | 2006 | 6 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2006 | 32 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2006 | 30 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2006 | 71 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 106 | 0.020 |
Why?
|
| Kidney | 1 | 2009 | 455 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2010 | 632 | 0.020 |
Why?
|
| Infection Control | 1 | 2006 | 105 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2006 | 208 | 0.010 |
Why?
|
| Sex-Determining Region Y Protein | 1 | 2004 | 1 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2006 | 490 | 0.010 |
Why?
|
| Hospital Units | 1 | 2004 | 9 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 114 | 0.010 |
Why?
|
| Electronics | 1 | 2004 | 35 | 0.010 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2003 | 2 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2003 | 47 | 0.010 |
Why?
|
| Tight Junctions | 1 | 2003 | 20 | 0.010 |
Why?
|
| Ketoglutaric Acids | 1 | 2002 | 7 | 0.010 |
Why?
|
| Critical Care | 1 | 2006 | 402 | 0.010 |
Why?
|
| Nucleosomes | 1 | 2004 | 189 | 0.010 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2002 | 2 | 0.010 |
Why?
|
| Ketone Oxidoreductases | 1 | 2002 | 2 | 0.010 |
Why?
|
| Hydrazines | 1 | 2002 | 10 | 0.010 |
Why?
|
| Mannitol | 1 | 2002 | 14 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 726 | 0.010 |
Why?
|
| Furosemide | 1 | 2002 | 20 | 0.010 |
Why?
|
| Sodium | 1 | 2002 | 61 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 89 | 0.010 |
Why?
|
| Alanine | 1 | 2002 | 51 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 88 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 620 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 771 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2002 | 135 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2003 | 575 | 0.010 |
Why?
|